



Daniel Karp

Chief Business Development Officer

Daniel leads our global business development team, which includes mergers & acquisitions, licensing, collaborations, alliance management, and integration. Under his leadership, the team evaluates external opportunities and executes business development transactions. These deals drive growth and accelerate Organon's strategy by building the company's pipeline and portfolio.

Prior to joining Organon, Daniel served as Executive Vice President, Corporate Development at Biogen. Previously, he held a number of positions of increasing responsibility at Pfizer, including VP, Head of BD for Worldwide Research & Development, and VP, Head of BD for Pfizer Vaccines, Oncology and Consumer Healthcare. Throughout his career, Daniel and his teams have executed M&A and collaboration deals totaling over \$80B in potential value. Most importantly, these transactions have brought new drugs, gene therapies, vaccines, devices, and technologies closer to the patients who need them. Earlier in his career, Daniel held roles in healthcare and life sciences strategy consulting.

Daniel has a B.S. in biology from Duke University and an M.B.A. from the Wharton School of the University of Pennsylvania. Currently, he serves as Director on the board of Cartesian Growth Corp II and previously served on the board of Cartesian Growth Corp, which combined with Tiedemann Group and Alvarium Investments.

About Organon Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women's health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon's existing products produce strong cash flows that support investments in innovation and future growth opportunities in women's health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit <http://www.organon.com> and connect with us on [LinkedIn](#), [Instagram](#), [X](#) and [Facebook](#).